Stockscreener 앱 받기
2.50%
전일 마감가:
$3.60
열려 있는:
$3.66
하루 거래량:
1.65M
Relative Volume:
0.31
시가총액:
$286.71M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.1555
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-4.88%
1개월 성능:
-20.77%
6개월 성능:
-47.30%
1년 성능:
-36.18%
1일 변동 폭
$3.49
$3.68
1주일 범위
$3.49
$3.74
52주 변동 폭
$2.90
$11.16
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.535 | 297.66M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.00 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.82 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.60 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.59 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Altimmune, Inc. (ALT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
ALT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
Shareholders Filed a Lawsuit Against Altimmune for Misleading Clinical Trial Disclosures - TradingView
Altimmune ($ALT) Misleading Pemvidutide Trial Results and Fibrosis Endpoint Failure Case - TradingView
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Applying chart zones and confluence areas to Altimmune Inc.Market Opportunity Tracker for Swing Traders - Newser
Order flow analysis tools used on Altimmune Inc.Free Earnings Play Trade Plan With Alerts - Newser
Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit - GlobeNewswire
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investor Alert: Deadline Approaching to Join Altimmune, Inc. (ALT) Class ActionContact Levi & Korsinsky - Newsfile
Altimmune, Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Altimmune Faces Legal Storm as Trial Results Disappoint - TipRanks
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Morningstar
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - PR Newswire
Altimmune Inc. stock momentum explainedPrice Forecast Based on AI Analysis - Newser
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Altimmune, Inc. Securities and Sets a Lead Plaintiff Deadline of October 6, 2025 - Business Upturn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
What makes Altimmune Inc. stock attractive to long term investorsFree Triple Return Setup with Risk Control - Newser
Altimmune reports Q2 2025 financial results on August 12. - AInvest
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | ALT Stock News - GuruFocus
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - The Manila Times
Why Altimmune Inc. stock attracts strong analyst attentionFree Weekly Return Pick Forecast Reports - Newser
Clinical-Stage Biotech Altimmune Sets Q2 2025 Earnings DateKey Details for Investors - Stock Titan
Analyzing recovery setups for Altimmune Inc. investorsFree Access to Smart Investment Tips - Newser
Levi & Korsinsky Investigates Altimmune, Inc. (ALT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Market reaction to Altimmune Inc.’s recent newsTechnical Insight Guide for Safer Trades - Newser
Published on: 2025-08-04 04:35:56 - Newser
Should I hold or sell Altimmune Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What are Altimmune Inc. company’s key revenue driversExtraordinary profit generation - Jammu Links News
Does Altimmune Inc. stock perform well during market downturnsRapid portfolio appreciation - Jammu Links News
What makes Altimmune Inc. stock price move sharplyCapitalize on high-growth stocks early - Jammu Links News
Is Altimmune Inc. a good long term investmentDynamic profit opportunities - Jammu Links News
Protect Your Investment: Contact Levi & Korsinsky About the Altimmune, Inc. (ALT) Investigation - ACCESS Newswire
What are the technical indicators suggesting about Altimmune Inc.Tremendous portfolio expansion - Jammu Links News
What catalysts could drive Altimmune Inc. stock higher in 2025Unlock powerful trading signals and alerts - Jammu Links News
How volatile is Altimmune Inc. stock compared to the marketCapitalize on momentum-driven stocks - jammulinksnews.com
How strong is Altimmune Inc. company’s balance sheetDiscover stocks with superior performance - Jammu Links News
Is Altimmune Inc. stock overvalued or undervaluedAchieve superior returns through strategic trading - Jammu Links News
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Altimmune Inc. stock performs during market volatilityReal Time Stock Movement and Alerts - Newser
What institutional investors are buying Altimmune Inc. stockFree Stock Data Feed Backed By Experts - Jammu Links News
Altimmune, Inc. (ALT) Stock Analysis: Exploring The 376.96% Potential Upside - DirectorsTalk Interviews
Is Altimmune Inc. reversing from oversold territorySafe Momentum Strategy With Trend Analysis - Newser
What is the risk reward ratio of investing in Altimmune Inc. stockExpert Picks Insights For Fast Growth - Jammu Links News
Altimmune Bets Big On Next-Gen Obesity And Liver Drugs - Finimize
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Published on: 2025-07-31 05:27:57 - Newser
How to use a screener to detect Altimmune Inc. breakoutsTechnical Reversal Pattern Summary and Tracker - Newser
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.53%
0.00%
자본화:
|
볼륨(24시간):